Stock Updates

How has Vertex Pharmaceuticals Incorporated:(NASDAQ:VRTX) performed recently?

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a large market cap stock with a market cap of 20978.68. It is in the Biotechnology industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of 26.03 and EPS of -1.65. At a stock price of 86.51 (-1.40%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 9.30%, more recently this last year it has grown by 26.50%. The next year growth is going to be about 202.73% and more long-term 51.20% after five years. EPS growth quarter over quarter is 79.40%. Sales growth for the past five years have been 48.40% and sales growth quarter over quarter is 187.40%.

For performance, Vertex Pharmaceuticals Incorporated the past week has seen a gain of 8.35%. For the last month performance for Vertex Pharmaceuticals Incorporated is -7.93%. While the last quarter is 2.79% and half year, -29.60%. Finally for the year, performance is -32.85%.

The 52-week high for Vertex Pharmaceuticals Incorporated, is at -39.69%, and for the 52-week low it comes to a value of 13.98%. The 20-day simple moving average is -0.55% and -13.41% for the 200-day simple moving average.

Volatility for the week is at 3.34%, and for the month it is 3.39%. Vertex Pharmaceuticals Incorporated, has a target price of 109.

In terms of debt, long term debt/equity is 0.69, and for total debt/equity Vertex Pharmaceuticals Incorporated has 0.86. The gross margin is 87.80%, while operating margin is -23.90%, the profit margin is -30.90%. The current ratio is 2.5 and the quick ratio is 2.4.

Insider ownership is at 0.50%, with instituitional ownership at 97.10%. Vertex Pharmaceuticals Incorporated has a payout ratio of *TBA. With the total shares outstanding coming to 242.5. The shares float is 242.5, with the float short at 2.84%, with short ratio coming to 3.78.

In terms of returns, the return on assets see Vertex Pharmaceuticals Incorporated, get -16.30%, with its returns on investment at -28.20%. Return on equity is -43.00%. So will the investors see the target price of 109, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Stephen Butters

Leave a Comment